{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T19:19:28Z","timestamp":1790882368715,"version":"4.1.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>Plasma ferritin levels above 4,420 ng\/mL have been proposed as a diagnostic marker for macrophage activation-like syndrome in sepsis and used for selection of sepsis patients for anti-inflammatory therapy. We here sought to determine the frequency, presentation, outcome, and host response aberrations of macrophage activation-like syndrome, as defined by admission ferritin levels above 4,420\u2009ng\/mL, in critically ill patients with community-acquired pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN:<\/jats:title>\n            <jats:p>A prospective observational cohort study.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>SETTING:<\/jats:title>\n            <jats:p>ICUs in two tertiary hospitals in the Netherlands.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PATIENTS:<\/jats:title>\n            <jats:p>One hundred fifty-three patients admitted with community-acquired pneumonia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MEASUREMENTS AND MAIN RESULTS:<\/jats:title>\n            <jats:p>Patients were stratified in community-acquired pneumonia\u2013macrophage activation-like syndrome (<jats:italic toggle=\"yes\">n<\/jats:italic> = 15; 9.8%) and community-acquired pneumonia\u2013control groups (<jats:italic toggle=\"yes\">n<\/jats:italic> = 138; 90.2%) based on an admission plasma ferritin level above or below 4,420\u2009ng\/mL, respectively. Community-acquired pneumonia\u2013macrophage activation-like syndrome patients presented with a higher disease severity and had a higher ICU mortality (46.7% vs 12.3% in community-acquired pneumonia\u2013controls; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.002). Twenty-three plasma biomarkers indicative of dysregulation of key host response pathways implicated in sepsis pathogenesis (systemic inflammation, cytokine responses, endothelial cell activation, and barrier function, coagulation activation) were more disturbed in community-acquired pneumonia\u2013macrophage activation-like syndrome patients. Hematologic malignancies were overrepresented in community-acquired pneumonia\u2013macrophage activation-like syndrome patients (33.3% vs 5.1% in community-acquired pneumonia\u2013controls; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.001). In a subgroup analysis excluding patients with hematologic malignancies (<jats:italic toggle=\"yes\">n<\/jats:italic> = 141), differences in mortality were not present anymore, but the exaggerated host response abnormalities in community-acquired pneumonia\u2013macrophage activation-like syndrome patients remained.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS:<\/jats:title>\n            <jats:p>Macrophage activation-like syndrome in critically ill patients with community-acquired pneumonia occurs more often in patients with hematologic malignancies and is associated with deregulation of multiple host response pathways.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ccm.0000000000005072","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T05:00:27Z","timestamp":1620018027000},"page":"1901-1911","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":17,"title":["Plasma Ferritin as Marker of Macrophage Activation-Like Syndrome in Critically Ill Patients With Community-Acquired Pneumonia"],"prefix":"10.1097","volume":"49","author":[{"given":"Xanthe","family":"Brands","sequence":"first","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floris M. C.","family":"de Vries","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Uhel","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bastiaan W.","family":"Haak","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hessel","family":"Peters-Sengers","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Schuurman","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjitske S. R.","family":"van Engelen","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Lutter","sequence":"additional","affiliation":[{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."},{"name":"Respiratory Medicine and Experimental Immunology, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf L.","family":"Cremer","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, University Medical Center Utrecht, Utrecht, the Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J.","family":"Bonten","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, the Netherlands."},{"name":"Julius Center for Health Sciences and Primary Care, University of Utrecht, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendon P.","family":"Scicluna","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."},{"name":"Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"van der Poll","sequence":"additional","affiliation":[{"name":"Center for Experimental and Molecular Medicine (CEMM), Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."},{"name":"Amsterdam Institute for Infection and Immunity, Amsterdam University Medical Centers, Amsterdam, The Netherlands."},{"name":"Division of Infectious Diseases, Amsterdam University Medical Centers - Location AMC, University of Amsterdam, Amsterdam, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,5,3]]},"reference":[{"key":"R2-20250502","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1164\/ajrccm.165.6.2103038","article-title":"Hospitalized community-acquired pneumonia in the elderly: Age- and sex-related patterns of care and outcome in the United States.","volume":"165","author":"Kaplan","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20250502","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1056\/NEJMoa1500245","article-title":"Community-acquired pneumonia requiring hospitalization among U.S. adults.","volume":"373","author":"Jain","year":"2015","journal-title":"N Engl J Med"},{"key":"R4-20250502","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock.","volume":"369","author":"Angus","year":"2013","journal-title":"N Engl J Med"},{"key":"R5-20250502","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (Sepsis-3).","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"R6-20250502","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2017.36","article-title":"The immunopathology of sepsis and potential therapeutic targets.","volume":"17","author":"van der Poll","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"R7-20250502","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","article-title":"How I treat hemophagocytic lymphohistiocytosis.","volume":"118","author":"Jordan","year":"2011","journal-title":"Blood"},{"key":"R8-20250502","doi-asserted-by":"crossref","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","article-title":"Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.","volume":"2","author":"Mehta","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"R9-20250502","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fimmu.2019.00055","article-title":"Macrophage activation-like syndrome: A distinct entity leading to early death in sepsis.","volume":"10","author":"Karakike","year":"2019","journal-title":"Front Immunol"},{"key":"R10-20250502","doi-asserted-by":"crossref","first-page":"764","DOI":"10.3899\/jrheum.100996","article-title":"An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis.","volume":"38","author":"Dav\u00ec","year":"2011","journal-title":"J Rheumatol"},{"key":"R11-20250502","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: Diagnosis, genetics, pathophysiology and treatment.","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"R12-20250502","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/rheumatology\/key006","article-title":"Macrophage activation syndrome in adults: Recent advances in pathophysiology, diagnosis and treatment.","volume":"58","author":"Carter","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20250502","doi-asserted-by":"crossref","first-page":"S82","DOI":"10.1016\/j.bbmt.2009.11.014","article-title":"Histiocytic disorders: Recent insights into pathophysiology and practical guidelines.","volume":"16","author":"Filipovich","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"key":"R14-20250502","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s12916-017-0930-5","article-title":"Macrophage activation-like syndrome: An immunological entity associated with rapid progression to death in sepsis.","volume":"15","author":"Kyriazopoulou","year":"2017","journal-title":"BMC Med"},{"key":"R15-20250502","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway.","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"key":"R16-20250502","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: Reanalysis of a prior phase III trial.","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"key":"R17-20250502","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1164\/rccm.201602-0368OC","article-title":"Comparative analysis of the host response to community-acquired and hospital-acquired pneumonia in critically ill patients.","volume":"194","author":"van Vught","year":"2016","journal-title":"Am J Respir Crit Care Med"},{"key":"R18-20250502","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1164\/rccm.201310-1875OC","article-title":"Association between source of infection and hospital mortality in patients who have septic shock.","volume":"189","author":"Leligdowicz","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"R19-20250502","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12026-014-8563-7","article-title":"sCD163 in AOSD: A biomarker for macrophage activation related to hyperferritinemia.","volume":"60","author":"Colafrancesco","year":"2014","journal-title":"Immunol Res"},{"key":"R20-20250502","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccc.2019.12.001","article-title":"Immune consequences of endothelial cells\u2019 activation and dysfunction during sepsis.","volume":"36","author":"Pons","year":"2020","journal-title":"Crit Care Clin"},{"key":"R21-20250502","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ccc.2019.11.002","article-title":"Platelet activation and endothelial cell dysfunction.","volume":"36","author":"van der Poll","year":"2020","journal-title":"Crit Care Clin"},{"key":"R22-20250502","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1097\/CCM.0b013e3182923712","article-title":"Interobserver agreement of centers for disease control and prevention criteria for classifying infections in critically ill patients.","volume":"41","author":"Klein Klouwenberg","year":"2013","journal-title":"Crit Care Med"},{"key":"R23-20250502","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS international sepsis definitions conference.","volume":"31","author":"Levy","year":"2003","journal-title":"Crit Care Med"},{"key":"R24-20250502","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1097\/01.CCM.0000215112.84523.F0","article-title":"Acute physiology and chronic health evaluation (APACHE) IV: Hospital mortality assessment for today\u2019s critically ill patients.","volume":"34","author":"Zimmerman","year":"2006","journal-title":"Crit Care Med"},{"key":"R25-20250502","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/BF01709751","article-title":"The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction\/failure. On behalf of the working group on sepsis-related problems of the European Society of Intensive Care Medicine.","volume":"22","author":"Vincent","year":"1996","journal-title":"Intensive Care Med"},{"key":"R26-20250502","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1164\/ajrccm.149.3.7509706","article-title":"The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination.","volume":"149","author":"Bernard","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"R27-20250502","doi-asserted-by":"crossref","first-page":"R204","DOI":"10.1186\/cc2872","article-title":"Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: The second international consensus conference of the acute dialysis quality initiative (ADQI) group.","volume":"8","author":"Bellomo","year":"2004","journal-title":"Crit Care"},{"key":"R28-20250502","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation.","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"R29-20250502","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19.","volume":"383","author":"Stone","year":"2020","journal-title":"N Engl J Med"},{"key":"R30-20250502","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.molmed.2014.01.007","article-title":"Why have clinical trials in sepsis failed?","volume":"20","author":"Marshall","year":"2014","journal-title":"Trends Mol Med"},{"key":"R31-20250502","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41581-019-0199-3","article-title":"Prognostic and predictive enrichment in sepsis.","volume":"16","author":"Stanski","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"R32-20250502","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ccc.2019.08.012","article-title":"Biomarkers and precision medicine: State of the art.","volume":"36","author":"Sarma","year":"2020","journal-title":"Crit Care Clin"},{"key":"R33-20250502","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s12185-015-1813-1","article-title":"Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting.","volume":"102","author":"Saeed","year":"2015","journal-title":"Int J Hematol"},{"key":"R34-20250502","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/SHK.0000000000001048","article-title":"Hemophagocytic lymphohistiocytosis: Potentially underdiagnosed in intensive care units.","volume":"50","author":"Lachmann","year":"2018","journal-title":"Shock"},{"key":"R35-20250502","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1097\/00003246-199206000-00025","article-title":"American College of Chest Physicians\/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis.","volume":"20","year":"1992","journal-title":"Crit Care Med"},{"key":"R36-20250502","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/joim.12331","article-title":"Endothelial barrier dysfunction in septic shock.","volume":"277","author":"Opal","year":"2015","journal-title":"J Intern Med"},{"key":"R37-20250502","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/SHK.0000000000000473","article-title":"The endothelium in sepsis.","volume":"45","author":"Ince","year":"2016","journal-title":"Shock"},{"key":"R38-20250502","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1097\/ALN.0000000000003122","article-title":"Sepsis-induced coagulopathy and disseminated intravascular coagulation.","volume":"132","author":"Iba","year":"2020","journal-title":"Anesthesiology"},{"key":"R39-20250502","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S0140-6736(13)61048-X","article-title":"Adult haemophagocytic syndrome.","volume":"383","author":"Ramos-Casals","year":"2014","journal-title":"Lancet"},{"key":"R40-20250502","doi-asserted-by":"crossref","first-page":"e1692","DOI":"10.1097\/MD.0000000000001692","article-title":"Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis.","volume":"94","author":"Valade","year":"2015","journal-title":"Medicine (Baltimore)"},{"key":"R41-20250502","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bjh.13102","article-title":"Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: Impact of triggering disease and early treatment with etoposide.","volume":"168","author":"Arca","year":"2015","journal-title":"Br J Haematol"},{"key":"R42-20250502","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1007\/s00134-010-1936-z","article-title":"Critical care management of patients with hemophagocytic lymphohistiocytosis.","volume":"36","author":"Buyse","year":"2010","journal-title":"Intensive Care Med"},{"key":"R43-20250502","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.hoc.2015.06.010","article-title":"Macrophage activation syndrome.","volume":"29","author":"Ravelli","year":"2015","journal-title":"Hematol Oncol Clin North Am"},{"key":"R44-20250502","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41572-019-0069-0","article-title":"Acute respiratory distress syndrome.","volume":"5","author":"Matthay","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"R45-20250502","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"}],"container-title":["Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000005072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T18:00:51Z","timestamp":1746208851000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCM.0000000000005072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,3]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ccm.0000000000005072","relation":{},"ISSN":["0090-3493"],"issn-type":[{"value":"0090-3493","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,3]]}}}